Pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

12011,441

16/131499

September 14, 2018

Pimobendan is used for reducing the heart size and/or delaying the onset of clinical symptoms in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), and/or delaying the onset of heart failure, preferably congestive heart failure, in a patient suffering from asymptomatic (occult, preclinical) heart failure, preferably congestive heart failure, due to mitral valve disease (MVD), wherein the patient is preferably a mammal, more preferably a human, a dog, a cat or a horse, and most preferably a dog.

Boehringer Ingelheim Vetmedica GmbH (Ingelheim am Rhein, DE)

1. A method of treating a dog suffering from asymptomatic (occult, preclinical) heart failure due to mitral valve disease (MVD), the method comprising administering to the dog an effective amount of a composition comprising pimobendan to effect a reduction in heart size of an already pathologically enlarged heart of the dog, wherein pimobendan is administered as two doses per day such that the total daily dosage is 0.5 mg/kg bodyweight.

2. The method of claim 1 , wherein the asymptomatic (occult, preclinical) heart failure due to mitral valve disease (MVD) is of stage ISACHC (International Small Animal Cardiac Health Council) Class I.

3. The method of claim 1 , wherein the pimobendan treatment effects a reduction of the heart size of the dog of at least 5%, wherein the reduction of the heart size is compared to a baseline before pimobendan treatment is initiated.

4. The method of claim 1 , wherein the daily pimobendan dose is administered as two doses of 0.25 mg/kg bodyweight.

5. The method of claim 1 , wherein pimobendan is administered orally or parenterally.

6. The method of claim 1 , wherein pimobendan is administered before, during or after administration of one or more additional active pharmaceutical ingredients selected from the group consisting of ACE inhibitors and diuretics.

7. The method of claim 6 , wherein pimobendan is administered concomitantly with benazepril and/or furosemide.

8. The method of claim 7 , wherein pimobendan is administered concomitantly with benazepril and furosemide.

9. The method of claim 1 , wherein pimobendan is administered orally in the form of a tablet or a capsule.

10. The method of claim 2 , wherein the asymptomatic (occult, preclinical) heart failure due to mitral valve disease (MVD) is of stage ISACHC (International Small Animal Cardiac Health Council) Class IA or Class IB, or of stage ISACHC Class IB, NYHA Class I and ACVIM stage B2.

11. The method of claim 1 , wherein the dog is suffering from asymptomatic (occult, preclinical) heart failure due to myxomatous mitral valve disease (MMVD).

12. The method of claim 3 , wherein the reduction of the heart size of the dog is obtained within 10 to 100 days of treatment with pimobendan.

13. The method of claim 3 , wherein the reduction of the heart size of the dog is at least 10%.

14. The method of claim 3 , wherein the reduction of the heart size of the dog is obtained within a period of days of about 30 to 40 days of treatment with pimobendan.

15. A method of treating a dog suffering from asymptomatic (occult, preclinical) heart failure due to mitral valve disease (MVD), the method comprising administering to the dog an effective amount of a composition comprising pimobendan to effect a reduction in heart size of an already pathologically enlarged heart of the dog, wherein the asymptomatic (occult, preclinical) heart failure due to mitral valve disease (MVD) is of stage ISACHC (International Small Animal Cardiac Health Council) Class IB, wherein pimobendan is administered as two doses per day such that the total daily dosage is 0.5 mg/kg bodyweight.

16. The method of claim 15 , wherein each dose of the two doses per day is administered such that the dog receives a dose every 12 hours.

17. The method of claim 1 , wherein each dose of the two doses per day is administered such that the dog receives a dose every 12 hours.

18. A method of treating a dog suffering from asymptomatic (occult, preclinical) heart failure due to myxomatous mitral valve disease (MMVD), the method comprising administering to the dog an effective amount of a composition comprising pimobendan to effect a reduction in heart size of an already pathologically enlarged heart of the dog and delay the onset of congestive heart failure, wherein the asymptomatic (occult, preclinical) heart failure due to myxomatous mitral valve disease (MMVD) is of ACVIM Stage B2 preclinical myxomatous mitral valve disease (MMVD), wherein pimobendan is administered twice a day such that the total daily dosage is 0.5 mg/kg bodyweight.

19. The method of claim 18 , wherein pimobendan is administered to the dog every 12 hours.

3574859 April 1971 Kosti
3822349 July 1974 Kosti
3832460 August 1974 Kosti
3839522 October 1974 Kosti
3950333 April 1976 Durant et al.
4128658 December 1978 Price et al.
4256743 March 1981 Goldhaber
4283400 August 1981 von Bittera et al.
4283408 August 1981 Hirata et al.
4293557 October 1981 Shibata et al.
4361563 November 1982 Austel et al.
4375547 March 1983 Pioch
4386099 May 1983 Cereda et al.
4427648 January 1984 Brickl et al.
4569837 February 1986 Suzuki et al.
4585790 April 1986 Padfield et al.
4596705 June 1986 Schepky et al.
4654342 March 1987 Slater
4704284 November 1987 Beatty et al.
4732915 March 1988 Ayer et al.
4851226 July 1989 Julian et al.
4865851 September 1989 James et al.
4868182 September 1989 Dage
4906628 March 1990 Coates
4933182 June 1990 Higashi et al.
4954501 September 1990 Herter et al.
4973469 November 1990 Mulligan et al.
5024998 June 1991 Bodor
5151420 September 1992 Backstrom et al.
5188836 February 1993 Muhammad et al.
5364646 November 1994 Gruber et al.
5569657 October 1996 Nore et al.
5571533 November 1996 Santus et al.
6407079 June 2002 Muller et al.
6476078 November 2002 Jerussi et al.
6669955 December 2003 Chungi et al.
6713487 March 2004 Yu et al.
7262165 August 2007 Lindenblatt et al.
8409612 April 2013 Criere et al.
8846679 September 2014 Folger et al.
8980894 March 2015 Daemmgen
9463199 October 2016 Daemmgen
9889148 February 2018 Daemmgen
10117869 November 2018 Daemmgen
10537588 January 2020 Daemmgen
20030059471 March 2003 Compton et al.
20030162835 August 2003 Staniforth et al.
20030165565 September 2003 Mehta
20030190343 October 2003 Thombre et al.
20030212114 November 2003 Sato
20040037869 February 2004 Cleverly et al.
20040152664 August 2004 Chang et al.
20040157887 August 2004 Whittle et al.
20050095293 May 2005 Brauns et al.
20050203097 September 2005 Folger et al.
20050239692 October 2005 Lindenblatt et al.
20070112010 May 2007 Kleeman et al.
20080207629 August 2008 Folger et al.
20090082282 March 2009 Daemmgen et al.
20100035889 February 2010 Daemmgen
20100166857 July 2010 Yan et al.
20100183718 July 2010 Ovaert et al.
20100273807 October 2010 Kleeman et al.
20110028457 February 2011 Roewer et al.
20110189283 August 2011 Derrieu et al.
20110251208 October 2011 Daemmgen et al.
20110318420 December 2011 Hu et al.
20120148640 June 2012 Folger et al.
20120308662 December 2012 Konishi et al.
20130115301 May 2013 Bele et al.
20130203690 August 2013 Daemmgen et al.
20140155338 June 2014 Daemmgen et al.
20140235648 August 2014 Folger et al.
20140363510 December 2014 Folger et al.
20150025082 January 2015 Aven et al.
20150064249 March 2015 Folger et al.
20150148335 May 2015 Bova et al.
20150150820 June 2015 Laczay
20160038420 February 2016 Brunel et al.
20170290829 October 2017 Schummer
20190008862 January 2019 Daemmgen
2012101682 January 2013
950833 July 1974
1222697 June 1987
2034569 July 1991
1336498 August 1995
1662250 August 2005
1929845 March 2007
3728244 March 1989
4001623 July 1991
0241179 October 1987
0256566 February 1988
0268146 May 1988
0306846 March 1989
0330052 August 1989
0335545 October 1989
0349657 January 1990
439030 July 1991
1123703 August 2001
1247456 October 2002
1260215 November 2002
1579862 September 2005
1903039 March 2008
1920785 May 2008
2338493 June 2011
3034071 June 2016
2350105 December 1977
1045031 October 1966
2228004 August 1990
61500788 April 1986
H029825 January 1990
H0489428 March 1992
H0570612 March 1993
H11228302 August 1999
2005281283 October 2005
2007191419 August 2007
2008504308 February 2008
2011157390 August 2011
2012533595 December 2012
2013006798 January 2013
2013503113 January 2013
1985002767 July 1985
1989004178 May 1989
1995031963 November 1995
0012137 March 2000
2000069414 November 2000
2001035925 May 2001
2001064190 September 2001
2001097861 December 2001
0245693 June 2002
2002049646 June 2002
2003012030 February 2003
03072141 September 2003
2003074032 September 2003
2003075895 September 2003
2003097067 November 2003
2003099194 December 2003
2004000317 December 2003
2004000344 December 2003
2004016252 February 2004
2004033444 April 2004
2004050657 June 2004
2004058726 July 2004
2004060353 July 2004
2004089418 October 2004
2005035505 April 2005
2005084647 September 2005
2005092343 October 2005
2005107756 November 2005
2005117911 December 2005
2006000229 January 2006
2006022562 March 2006
2006060122 June 2006
2006060127 June 2006
2007036671 April 2007
2007038796 April 2007
2007054514 May 2007
2007112274 October 2007
2007128749 November 2007
2008055871 May 2008
2009060226 May 2009
2010010257 January 2010
2010055119 May 2010
2010060874 June 2010
2011009818 January 2011
2011042463 April 2011
2011076738 June 2011
2013024023 February 2013
2013135852 September 2013
2013164473 November 2013
2013170317 November 2013
2014136035 September 2014
2015082389 June 2015
2017174571 October 2017

Atkins et al., “Pharmacologic management of myxomatous mitral valve disease in dogs”, Journal of Veterinary Caroliology, vol. 14, No. 1, Feb. 2012, pp. 165-184. cited by applicant
Ouellet et al., “Effect of Pimobendan on Echocardiographic Values in Dogs with Asymptomatic Mitral Valve Disease”, Journal of Veterinary Internal Medicine, vol. 23. No. 2, Jan. 2009, pp. 258-263. cited by applicant
Chetboul et al., “Comparative Adverse Cardiac Effects of Pimobendan and Benazepril Monotherapy in Dogs with Mild Degenerative Mitral Valve Disease: A Prospective, Controlled, Blinded, and Randomized Study”, Journal of Veterinary Internal Medicine, 2007; 21, pp. 742-753. cited by applicant
Boswood et al., 2011, “Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease”, The Veterinary Record, vol. 68, No. 8, Feb. 2011, p. 222. cited by applicant
Boswood et al., “Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: the EPIC Study—A randomized Clinical Trial”, Journal of Veterinary Internal Medicine, vol. 30, No. 6, Sep. 2016, pp. 1765-1779. cited by applicant
Beaufrere et al., “Pimobendan”, Journal of Exotic Pet Medicine, vol. 18, No. 4, Oct. 2009, pp. 311-313. cited by applicant
PCT International Search Report, PCT/EP2017/057970, dated Jun. 1, 2017, 5 pages. cited by applicant
PCT Written Opinion of the International Searching Authority, PCT/EP2017/057970, dated Jun. 1, 2017, 6 pages. cited by applicant
Fox et al., “Bradykinin-evoked sensitization of airway sensory nerves: A mechanism for ACE-inhibitor cough.” Nature Medicine, vol. 2, No. 7, Jul. 1996, pp. 814-817. cited by applicant
International Search Report and Written Opinion for PCT/EP2017/057970 dated Jun. 12, 2017. cited by applicant
Vromans et al., “Densification properties and compactibility of mixtures of pharmaceutical excipients with and without magnesium stearate.” International Journal of Pharmaceutics, vol. 46, 1988, pp. 183-192. cited by applicant
Liu et al., “Pharmacology Preparation Technology.” Chemical Industry Press, 2006, pp. 113-114. cited by applicant
Sun et al., “Pimobendan.” Chemical Industry Press, 2002, pp. 29-30. cited by applicant
Swedish University of Agricultural Sciences, Press Release dated Mar. 13, 2015, made publicly available at the webpage having the URL https://www.mynewsdesk.com/se/sveriges_lantbruksuniversitet_slu/pressreleases/the-epic-study-has-been-terminated-1130220. cited by applicant
Elliott, P., “Diagnosis and management of dilated cardiomyopathy”. Heart, vol. 83, 2000, pp. 106-112. cited by applicant
Endoh, Masao, “New Aspects of the Treatment of Myocardial Failure from a Pharmacological Standpoint”. Journal of Clinical and Experimental Medicine, vol. 187, No. 10, 1998, pp. 827-831. cited by applicant
Erhardt, L., “An Emerging Role for Calcium Sensitisation in the Treatment of Heart Failure”. Expert Opinion on Investigational Drugs, vol. 14, No. 6, 2005, pp. 659-670. cited by applicant
Ettinger et al., “Effects of enalapril maleate on survival of dogs with naturally acquired heart failure”. Journal of the American Veterinary Medical Association, vol. 213, No. 11, 1998, pp. 1573-1577. cited by applicant
Ettinger et al., “Therapeutic Considerations in Medicine and Disease”. Textbook of Veterinary Internal Medicine, Diseases of the Dog and Cat, Sixth Edition, vol. I, 2004, pp. 530-531. cited by applicant
Fitton et al., “Pimobendan. A Review of its Pharmacology and Therapeutic Potential in Congestive Heart Failure”. Drugs and Aging, vol. 4, No. 5, 1994, pp. 417-441. cited by applicant
Fox et al., “Prosepective Double-Blinded, Multicenter Evaluation of Chronic Therapies for Feline Diastolic Heart Failure: Interim Analysis”. ACVIM Abstracts, Abstract 78, 2003, pp. 398-399. cited by applicant
Fox, Philip R., “Hypertrophic Cardiomyopathy. Clinical and Pathologic Correlates”. Journal of Veterinary Cardiology, vol. 5, No. 2, Nov. 2003, pp. 39-45. cited by applicant
Fraker et al., “Reversal of phosphate induced decreases in force by the benzimidazole pyridazinone, UD-CG 212 CL, in myofilaments from human ventricle.” Molecular and Cellular Biochemistry, vol. 176, 1997, pp. 83-88. cited by applicant
Fuentes, et al., “A Double-Blind, Randomized, Placebo-Controlled Study of Pimobendan in Dogs with Dilated Cardiomyopathy,” Journal of Veterinary Internal Medicine, vol. 16, 2002, pp. 255-261. cited by applicant
Fujino et al., “Differential Effects of d-and I-Pimobendan on Cardia Myofilament Calcium Sensitivity1”. The Journal of Pharmacology and Experimental Therapeutics, vol. 247, No. 2, 1988, pp. 519-523. cited by applicant
Goineau et al., “Cardiomyopathie Syrian Hamster as a Model of Congestive Heart Failure”. Current Protocols in Pharmacology, Supp. 42, Unit 5.50, John Wiley & Sons, Inc., Sep. 2008, 12 pages. cited by applicant
Groban, Leanne, “Diastolic Dysfunction in the Older Heart”. Journal of Cardiothoracic and Vascular Anesthesia, vol. 19, No. 2, Apr. 2005, pp. 228-236. cited by applicant
Gwathmey et al., “Abnormal Intracellular Calcium Handling in Myocardium From Patients With End-Stage Heart Failure”. Circulation Research, vol. 61, No. 1, 1987, pp. 70-76. cited by applicant
Hasenfuss et al., “Influence of the calcium-sensitizer UDCG-115 on hemodynamics and myocardial energetics in patients with idiopathic dilated cardiomyopathy. Comparison with nitroprusside”. Basic Research Cardiology, vol. 84, No. 1, 1989, pp. 225-233. cited by applicant
Hauf et al., “Acute and Long-Term Hemodynamic Effects of Pimobendan (UD-CG 115 BS) in Comparison with Captopril”. Journal of Cardiovascular Pharmacology, vol. 15, Supp. 2, 1989, pp. S49-S56. cited by applicant
Hemati et al., “Fluidized bed coating and granulation: influence of process-related variables and physicochemical properties on the growth kinetics”. Powder Technology, vol. 13, 2002, pp. 18-34. cited by applicant
Häggstrom et al., “Effect of Pimobendan or Benazepril Hydrochloride on Survival Times in Dogs with Congestive Heart Failure Caused by Naturally Occurring Myxomatous Mitral Valve Disease: The QUEST Study”. Journal of Veterinary Internal Medicine, vol. 22, 2008, pp. 1124-1135. cited by applicant
Häggstrom et al., “Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and aboratory Variables in Dogs with Myxomatous Mitral Valve Disease Rexceiving Pimobendan or Benazepril: The QUEST Study”. Journal of Veterinary Internal Medicine, 2013, pp. 1-11. cited by applicant
Häggström et al., “Effects of long-term treatment with enalapril or hydralazine on the renin-angiotension-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation”. American Journal of Veterinary Research, vol. 57, No. 11, Nov. 1996, pp. 1645-1662. cited by applicant
Häggström et al., “New insights into degenerative mitral valve disease in dogs”. Veterinary Clinics Small Animal Practice, vol. 34, 2004, pp. 1209-1226. cited by applicant
Iwasaki et al., “Pimobendan Inhibits the Production of Proinflammatory Cytokines and Gene Expression of Inducible Nitric Oxide Synthase in a Murine Model of Viral Myocarditis”. Journal of the American College of Cardiology, vol. 33, No. 5, 1999, pp. 1400-1407. cited by applicant
Jain et al., “Effects of Milrinone on Left Ventricular Remodeling After Acute Myocardial Infarction”. Circulation, vol. 84, No. 2, Aug. 1991, pp. 798-804. cited by applicant
Kashem et al., “CardioClasp: A New Passive Device to Reshape Cardiac Enlargement”. ASAIO Journal, vol. 48, No. 3, 2002, pp. 253-259. cited by applicant
Kato et al., “Clinical Evaluation of Pimobendan (UD-CG115BS) for Chronic Heart Failure—A Multicentre Placebo-Controlled Double Blind Study”. Journal of Clinical Therapeutics & Medicines, vol. 8, No. 6, 1992, pp. 1311-1351. cited by applicant
Kato, Kazuzo, “Clinical Efficacy and Safety of Pimobendan in Treatment of Heart Failure-Experience in Japan”. Cardiology, vol. 88, Supp. 2, 1997, pp. 28-36. cited by applicant
Katz et al., “A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure”. American Heart Journal, vol. 123, 1992, pp. 95-103. cited by applicant
Kittleson et al., “The Acute Hemodynamic Effects of Milrinone in Dogs With Severe Idiopathic Myocardial Failure”. Journal of Veterinary Medicine, vol. 1, 1987, pp. 121-127. cited by applicant
Kitzen et al., “Pimobendan”. Cardiovascular Drug Reviews, vol. 6, No. 4, 1988, pp. 265-291. cited by applicant
Koob et al., “Acute Effects of Furosemide on Blood Electrolytes and Hemodynamics in Dogs”. Angiology, 1978, pp. 463-472. cited by applicant
Kubo et al., “Beneficial Effects of Pimobendan on Exercise Tolerance and Quality of Life in Patients with Heart Failure. Results of a Multicenter Trial”. Circulation, vol. 85, No. 3, Mar. 1992, pp. 942-949. cited by applicant
Kvart et al., “Efficacy of Enalapril for Prevention of Congestive Heart Failure in Dogs with Myxomatous Valve Disease and Asymptomatic Mitral Regurgitation”. Journal of Veterinary Internal Medicine, vol. 16, 2002, pp. 80-88. cited by applicant
Lachman et al., “The Theory and Practice of Industrial Pharmacy”., 3rd Edition, Lea & Febiger, Philadelphia, 1986, pp. 58-60. cited by applicant
Lai et al., “Real Time and Noninvasive Monitoring of Dry Powder Blend Homogeneity”. AlChE Journal, vol. 47, No. 11, Nov. 2001, pp. 2618-2622. cited by applicant
Lamb et al., “Assessment of the value of the vertebral heart scale in the radiographic diagnosis of cardia disease in dogs”. Veterinary Record, vol. 146, 2000, pp. 687-690. cited by applicant
Lantz et al., “Stability of nizatidine in extemporaneous oral liquid preparations”. American Journal of Hospital Pharmacy, vol. 47, No. 12, Dec. 1990, pp. 2716-2719. cited by applicant
Lewis et al., “Near-Infrared Chemical Imaging for Product and Process Understanding”. in Process Analytical Technology, Second Edition, John Wiley & Sons, Ltd., United Kingdom, 2010, pp. 272-276. cited by applicant
Lewis, Alan B., “Clinical Profile and Outcome of Restrictive Cardiomyopathy in Children”. American Heart Journal, vol. 123, No. 6, 1992, pp. 1589-1593. cited by applicant
Lezcano et al., “Complexation of Several Benzimidazole-Type Fungicides with Alpha and Beta-Cyclodextrins”. Journal of Agricultural and Food Chemistry, vol. 50, 2002, pp. 108-112. cited by applicant
Lip et al., “ABC of heart failure: Aetiology”. British Medical Journal, vol. 320, Jan. 2000, pp. 104-107. cited by applicant
Liu et al., “Cardiovascular Pathology: The Role of Cardiovascular Pathology in Practice”. Textbook of Canine and Feline Cardiology: Principles and Clinical Practice, Second Edition, Chapter 36, Saunders, 1999, pp. 817-844. cited by applicant
Loew, Earl R., “Gastric Secretion in Dogs Treated with Histamine Antagonist, Thymoxyethyldiethylamine”. Experimental Biology and Medicine, vol. 48, No. 1, Oct. 1941, pp. 65-68. cited by applicant
Loftsson et al., “Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization”. Journal of Pharmaceutical Sciences, vol. 85, No. 10, Oct. 1996, pp. 1017-1025. cited by applicant
Lombard et al., “Clinical Efficacy of Pimobendan Versus Benazepril for the Treatment of Acquired Atrioventricular Valvular Disease in Dogs”. Journal of the American Animal Hospital Association, vol. 42, No. 4, Jul./Aug. 2006, pp. 249-261. cited by applicant
Lombard, Christophe W., “Therapy of Congestive Heart Failure in Dogs with Pimobendan”. Proceedings of the 18th Annual Veterinary Medical Forum, American College of Veterinary International Medicine, Seattle, WA, 2000, pp. 107-109. cited by applicant
Lord et al., “Radiology: Role of Radiology in Diagnosis and Management of Thoracic Disease”. Textbook of Canine and Feline Cardiology: Principles and Clinical Practice, Second Edition, Chapter 7, Saunders, 1999, pp. 111-117. cited by applicant
Luis-Fuentes, Virginia, “The effect of pimobendan in English Cocker Spaniels and Doberman dogs with heart failure and idiopathic dilated cardiomyopathy (DCM)”. Ingelheimer Dialog, Boehringer Inglehim Vetmedica GmbH, Jun. 2000, Frankfort/Mainz, pp. 8-11. cited by applicant
Lyon et al., “Near-Infrared Spectral Imaging for Quality Assurance of Pharmaceutical Products: Analysis of Tablets to Assess Powder Blend Homogeneity”. AAPS PharmSciTech, vol. 3, No. 3, Art. 17, Sep. 2002, pp. 1-15. cited by applicant
Malik et al., “Permethrin Spot-On Intoxication of Cats: Literature review and survey of veterinary practitioners in Australia”. Journal of Feline Medicine and Surgery, vol. 12, 2010, pp. 5-14. cited by applicant
Mamoru et al., “Effects of Long-term, Very-low-dose Pimobendan for Patients with Diastolic Heart Failure”. Journal of Cardial Failure, vol. 12, No. 8, Oct. 2006, p. S171. cited by applicant
“905 Uniformity of Dosage Units”. 2011 The United States Pharmacopeial Convention, Stage 6 Harmonization, Dec. 1, 2011, pp. 1-3. cited by applicant
“Cardiovascular system”. MIMS, IVS Annual, Chapter 5, 2003, p. 104. cited by applicant
“Citric Acid”. The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 13th Edition, Merck Research Laboratories Division of Merck & Co., Inc., Whitehouse Station, NJ, Index 2350, 2001, pp. 405-406. cited by applicant
“Guidance for Industry, Container Closure Systems for Packaging Human Drugs and Biologics: Chemistry, Manufacturing, and Controils Documentation”. U.S. Department of Health and Human Services Food and Drug Administration, May 1999, pp. 1-56. cited by applicant
“Pharmaceutical Necessities”. Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Company, Easton, Pennsylvania, Chapter 66, 1990, pp. 1288-1300. cited by applicant
“Pimobendan”. The Merck Index, An Encyclopedia of Chemicals, Drugs, and Biologicals, 13th Edition, Merck Research Laboratories Division of Merck & Co., Inc., Whitehouse Station, NJ, Index 7515, 2001, p. 1332. cited by applicant
“Rimadyl F 50 mg”. Summary of Product Characteristics, Zoetis France, May 15, 2013, pp. 1-4. cited by applicant
“Vetmedin®—1,25 mg appetizing tablets for dogs Veterinary use”. Summary of Product Characteristics, SCS Boehringer Ingelheim Comm. V, Mar. 25, 2009, pp. 1-4. cited by applicant
Abstract in English for DE3728244, 1989. cited by applicant
Abstract in English for EP0306846, 1989. cited by applicant
Abstract in English for EP0330052, 1989. cited by applicant
Abstract in English for JP2005281283, 2005. cited by applicant
Abstract in English for JPH0489428, 1992. cited by applicant
Abstract in English of JPH0570612, 1993. cited by applicant
Abstract in English of JPH11228302, 1999. cited by applicant
Ahmed et al., “Pharmaceutical challenges in veterinary product development”. Advanced Drug Delivery Reviews, vol. 54, 2002, pp. 871-882. cited by applicant
Asanoi et al., “Disparate Inotropic and Lusitropic Responses to Pimobendan in Conscious Dogs with Tachycardia-Induced Heart Failure”. Journal of Cardiovascular Pharmacology, vol. 23, No. 2, 1994, pp. 268-274. cited by applicant
Ash et al., “Receptor Mediating Some Actions of Histamine”. British Journal of Pharmacology and Chemotherapy, vol. 27, No. 2, Aug. 1996, pp. 427-439. cited by applicant
Atkins et al., “Guidelines for the Diagnosis and Treatment of Canine Chronic Valvular Heart Disease”. Journal of Veterinary Internal Medicine, vol. 23, No. 6, 2009, pp. 1-9. cited by applicant
Banker et al., “Uniformity of Dosage Units”. Modern Pharmaceutics, Fourth Edition, Revised and Expanded, Marcel Dekker, Inc., New York, NY, 2006, p. 498. cited by applicant
Bassani et al., “Enhanced Water-Solubility of Albendazole by Hydroxy-Propyl-ß-Cyclodextrin Complexation”. Journal of Inclusion Phenomena and Molecular Recognition in Chemistry, vol. 25, No. 1-3, Mar. 1996, pp. 149-152. cited by applicant
Bastien et al., “Chronic AT receptor blockade and angiotensin-converting enzyme (ACE) inhibition in (CHF 146) cardiomyopathie hamsters: effects on cardiac hypertrophy and survival”. Cardiovascular Research, vol. 43, 1999, pp. 77-85. cited by applicant
Baur et al., “Cardiac remodelling and myocardial contractility in patients with congestive heart failure treated with furosemide and enalapril”. Basic Research in Cardiology, vol. 86, Supp. 1, 1991, pp. 157-163. cited by applicant
Beers, et al., Merck Manual of Diagnosis and Therapy, 17th Edition, Chapter 203, Section 16, Merck Research Laboratories, Whitehouse Station, NJ, USA, 1999, pp. 1688-1692. cited by applicant
Berny et al., “Review: Animal Poisoning in Europe. Part 2: Companion Animals”. The Veterinary Journal, vol. 193, 2010, pp. 255-259. cited by applicant
Black et al., “Definition and Antagonism of Histamine H2-receptors”. Nature, vol. 236, Apr. 1972, pp. 385-390. cited by applicant
Boehringer Ingelheim Vetmedica GmbH, 1st International Canine Valvular Disease Symposium, Paris, Oct. 30-31, 2004, pp. 1-45. cited by applicant
Boehringer Ingelheim Vetmedica, Inc. “Freedom of Information Summary: Original New Animal Drug Application”. NADA 141-273, Vetmedin, Pimobendan Chewable Tablets, Apr. 30, 2007, pp. 1-46. cited by applicant
Borgarelli et al., “Canine Idiopathic Dilated Cardiomyopathy. Part II: Pathophysiology and therapy”. The Veterinary Journal, vol. 162, 2001, pp. 182-195. cited by applicant
Bozzone, Scott, “Solid Oral Dosage Forms Powder Blending” and “Solid Oral Dosage Forms, Blend Uniformity: Principles and Examples”. Pfizer, IKEV Meeting, May 31, 2001, pp. 1-66. cited by applicant
Brewster et al., “Cyclodextrins as pharmaceutical solubilizers”. Advanced Drug Delivery Reviews, vol. 59, No. 7, 2007, pp. 645-666. cited by applicant
Buchanan et al. “Vertebral scale system to measure canine heart size in radiographs”. Journal of the American Veterinary Medical Association, vol. 206, No. 2, Jan. 1995, pp. 194-199. cited by applicant
Burlage et al., “Other Pharmaceutical Adjuncts”., Physical and Technical Pharmacy, The Blakiston Division: The McGraw-Hill Book Company, Inc., New York, 1963, pp. 653-662. cited by applicant
Calvert et al., “Congestive cardiomyopathy in Doberman Pinscher dogs”. Journal of the American Veterinary Medical Association, vol. 181, 1982, pp. 598-602. cited by applicant
Calvert et al., “Signalment, Survival, and Prognostic Factors in Doberman Pinschers With End-Stage Cardiomyopathy”. Journal of Veterinary Internal Medicine, vol. 11, No. 6, 1997, pp. 323-326. cited by applicant
Cambridge Dictionary, homogeneous, Last Accessed Feb. 10, 2011, 1 page, http://dictionary.cambridge.org/dictionary/british/homogeneous. cited by applicant
Chambers 21st Century Dictionary, homogeneous, Last Accessed Feb. 10, 2011, 1 page, http://www.xreferplus.com/entry/chambdict/homogeneous. cited by applicant
Chetboul, et al., “Comparitive Adverse Cardiac Effects of Pimobendan and Benazepril Monotherapy in Dogs with Mild Degenerative Mitral Valve Disease: A Prospective, Controlled, Blinded, and Randomized Study”. Journal of Veterinary Internal Medicine, vol. 21, 2007, pp. 742-753. cited by applicant
Choy et al., “Scaling of myocardial mass to flow and morphometry of coronary arteries”. Journal of Applied Physiology, vol. 104, 2008, pp. 1281-1286. cited by applicant
Cohn et al., “Cardiac Remodeling-Concepts and Clinical Implications: A Consensus Paper From an International Forum on Cardiac Remodeling”. Journal of the American College of Cardiology, vol. 35, No. 3, 2000, pp. 569-582. cited by applicant
Collins English Dictionary, homogeneous, Last Accessed Feb. 10, 2011, 1 page, http://xreferplus.com/entry/hcengdict/homogeneous. cited by applicant
Conlon, P.D., “Nonsteroidal Drugs Used in the Treatment of Inflammation”. Veterinary Clinics of North America: Small Animal Practice, vol. 18, No. 6, Nov. 1988, pp. 1115-1131. cited by applicant
Cowley et al., “Treatment of severe heart failure: quantity or quality of life? A trial of enoximone”. , British Heart Journal, vol. 72, 1994, pp. 226-230. cited by applicant
Côté et al., “Congestive Heart Failure”. Feline Cardiology, Ch. 19, Wiley-Blackwell, ISBN 978-0-8138-1242-7, 2011, p. 259. cited by applicant
Deneke et al., “Medikamentöse Therapie der Herzinsuffizienz”. Herzschr Elektrophys, vol. 15, Suppl. 1, 2004, pp. 1/74-1/80. cited by applicant
Dews et al., “The Antihistamine Substance 2786 R.P.” British Journal of Pharmacology, vol. 1, 1946, pp. 278-286. cited by applicant
Dictionary of Veterinary Drugs and Animal Health Products Marketed in France, 12th Edition, 2003, 3 pages. cited by applicant
El-Hagrasy et al., “A Process Analytical Technology Approach to Near-Infrared Process Control of Pharmaceutical Power Blending: Part II: Qualitative Near-Infrared Models for Prediction of Blend Homogeneity”. Journal of Pharmaceutical Sciences, vol. 95, No. 2, Feb. 2006, pp. 407-421. cited by applicant
El-Hagrasy et al., “Near-Infrared Spectroscopy and Imaging for the Monitoring of Powder Blend Homogeneity”. Journal of Pharmaceutical Sciences, vol. 90, No. 9, Sep. 2001,. pp. 1298-1307. cited by applicant
Matsumori et al., “Pharmacology letters: Accelerated Communication: Pimobendan inhibits the activation of transcription factor NF-Kb A mechanism which explains its inhibition of cytokine production and inducible nitric oxide synthase”. Life Sciences, vol. 67, 2000, pp. 2513-2519. cited by applicant
McCrohon et al., “Differentiation of Heart Failure Related to Dilated Cardiomyopathy and Coronary Artery Disease Using Gadolinium-Enhanced Cardiovascular Magnetic Resonance”. Circulation, vol. 108, Jul. 2003, pp. 54-59. Originally published online Jun. 23, 2003, http://circ.ahajournals.org, 7 pages. cited by applicant
Medline, homogeneous, Merriam-Webster, Last Accessed Feb. 10, 2011, 1 page, http://www.merriam-webster.com/medlineplus/homogeneous. cited by applicant
Menard et al., “Physico-Chemical Aspects of the Complexation of Some Drugs with Cyclodextrins”. Drug Development and Industrial Pharmacy, vol. 16, No. 1, 1990, pp. 91-113. cited by applicant
Merriam-Webster, homogeneous, Last Accessed Feb. 10, 2011, 2 pages, http://www.merriam-webster.com/dictionary/homogeneous. cited by applicant
Monnet et al., “Idiopathic Dilated Cardiomyopathy in Dogs: Survival and Prognostic Indicators”. 1995, Journal of Veterinary Internal Medicine, vol. 9, No. 1, pp. 12-17. cited by applicant
Nakamoto et al., “The role of ascorbic acid deficiency in human gingivitis—a new hypothesis”. Journal of Theoretical Biology, vol. 108, No. 2, May 1984, pp. 163-171. cited by applicant
Ng, Tien M.H., “Levosimendan, a New Calcium-Sensitizing Inotrope for Heart Failure”. Pharmacotherapy, vol. 24, No. 10, 2004, pp. 1366-1384. cited by applicant
O'Grady, et al., “Does Angiotensin Converting Enzyme Inhibitor Therapy Delay the Onset of Congestive Heart Failure or Sudden Death in Doberman Pinschers with Occult Dilated Cardiomyopathy?” Acvim Abstracts, 1997, p. 138. cited by applicant
Ohte et al., “The Cardia Effects of Pimobendan (But Not Amrinone) Are Preserved at Rest and During Exercise in Conscious Dogs with Pacing-Induced Heart Failure”. The Journal of Pharmacology and Experimental Therapeutics, vol. 282, No. 1, 1997, pp. 23-31. cited by applicant
Okazaki et al., “A genetic linkage map of the Syrian hamster and localization of cariomyopathy locus on chromosome 9qa2.1-b1 using RLGS spot-mapping”. Nature Genetics, vol. 13, May 1996, pp. 87-90. cited by applicant
Packer et al., “Effect Of Oral Milrinone On Mortality In Severe Chronic Heart Failure.” The New England Journal of Medicine, vol. 325, No. 21, Nov. 1991, pp. 1468-1475. cited by applicant
Pagel et al., “Comparison of the effects of levosimendn, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency”. Basic Respiratory Cardiology, vol. 91, 1996, pp. 296-307. cited by applicant
Pagel et al., “Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs”. British Journal of Pharmacology, vol. 119, 1996, pp. 609-615. cited by applicant
Permanetter et al., “Acute Effects of Intraveneous UD-CG 115 BS (Pimobendan) on the Cardiovascular System and Left Ventricular Pump Function”. Journal of Cardiovascular Pharmacology, vol. 14, Supp. 2, 1989, pp. S36-S40. cited by applicant
Pernsteiner et al., “Effect of Topical Application of Phenylephrine Hydrochloride on Hyperplastic Gingivitis”. Journal of Periodontology, vol. 48, No. 8, Aug. 1977, pp. 473-477. cited by applicant
Petit et al., “VETMEDIN® 1.25 mg, VETMEDIN® 5 mg, Chewable tablets, Inodilator (pimobendan) tablet for dogs”. Dictionary of Veterinary Drugs and Animal Health Products Marketed in France, 16th Edition, Les Editions du Point Vétérinaire, 2011, pp. 1658-1661. cited by applicant
Phillips et al., “The challenge of gene therapy and DNA delivery”. Journal of Pharmacy and Pharmacology, vol. 53, 2001, pp. 1169-1174. cited by applicant
Piel et al., “Development of a parenteral and of an oral formulation of albendazole with cyclodextrins”. S.T.P. Pharma Sciences, vol. 9, No. 3, 1999, pp. 257-260. cited by applicant
Pirollo et al., “Targeted Delivery of Small Interfering RNA: Approaching Effective Cancer Therapies”. Cancer Research, vol. 68, No. 5, Mar. 2008, pp. 1247-1250. cited by applicant
Rackley, Charles E., “Diseases of the Heart and Pericardium”., The Merck Manual, Chapter 25, 16th Edition, 1992, pp. 446-459. cited by applicant
Redenti et al., “Drug/Cyclodextrin/Hydroxy Acid Multicomponent Systems. Properties and Pharmaceutical Applications”. Journal of Pharmaceutical Sciences, vol. 89, 2000, pp. 1-8. cited by applicant
Remme et al., “Hemodynamic Effects of Intravenous Pimobendan in Patients with Left Ventricular Dysfunction”. Journal of Cardiovascular Pharmacology, vol. 15, Supp. 2, 1989, pp. S41-S44. cited by applicant
Remme et al., “Hemodynamic, Neurohumoral, and Myocardial Energetic Effects of Pimobendan, a Novel Calcium-Sensitizing Compound, in Patients with Mild to Moderate Heart Failure”. Journal of Cardiovascular Pharmacology, vol. 24, No. 5, 1994, pp. 730-739. cited by applicant
Rinsyo to Kenkyu, “A case of diastolic hypertrophic cardiomyopathy in which sinus bradycardia and associated cardiac failure were improved as a result of cilostazol administration.” The Japanese Journal of Clinical and Experimental Medicine, vol. 83, No. 5, May 2006, pp. 125-130. cited by applicant
Rodriguez, Damon B., “Treatment of Feline Hypertrophic Cardiomyopathy*”. Compendium, vol. 24, No. 6, Jun. 2002, pp. 470-476. cited by applicant
Roland et al., “The Use of Pimobendan in Feline Heart Failure Secondary to Spontaneous Heart Disease”. The 18th Annual ECVIM Congress, Abstract, Belgium, Sep. 2008, 1 page. cited by applicant
Rudnic et al., “Oral Solid Dosage Forms”. Remington: The Science and Practice of Pharmacy, 20th Edition, Lippincott Williams & Wilkins, Baltimore, Maryland, Chapter 45, 2000, pp. 858-870. cited by applicant
Saavedra et al., “Reverse Remodeling and Enhanced Adrenergic Reserve From Passive External Support in Experimental Dilated Heart Failure”. Journal of the American College of Cariology, vol. 39, No. 12, 2002, pp. 2069-1076. cited by applicant
Sabbah et al., “Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfuntion and dilation in dogs with reduced ejection fraction”. Circulation, vol. 89, 1994, pp. 2852-2859. cited by applicant
Sabbah, Hani N., “The Cardiac Support Device and the Myosplint: Treating Heart Failure by Targeting Left Ventricular Size and Shape”. The Annals of Thoracic Surgery, vol. 75, 2003, pp. S13-S19. cited by applicant
Shiga et al., “b-Blocker Therapy Combined with Low-Dose Pimobendan in Patients with Idiopathic Dilated Cardiomyopathy and Chronic Obstructive Pulmonary Disease: Report on Two Cases”. Cardiovascular Drugs and Therapy, vol. 16, 2002, pp. 259-263. cited by applicant
Sisson et al., “Myocardial Diseases of Dogs”. Textbook of Canine and Feline Cardiology: Principles and Clinical Practice, Second Edition, Chapter 27, Saunders, 1999, pp. 581-619. cited by applicant
Sisson, David, “Lecture Notes: Cardiology”, The District of Columbia Academy of Veterinary Medicine, May 2001, pp. 1-18. cited by applicant
Stuber et al., “The Pharmaceutical and Biological Availability of Commercial Preparations of Furosemide”. Arzneimittel-Forschung, vol. 32, No. 6, 1982, pp. 693-697. cited by applicant
Summerfield et al., “Efficacy of Pimobendan in the Prevention of Congestive Heart Failure or Sudden Death in Doberman Pinschers with Preclinical Dilated Cardiomyopathy (The PROTECT Study)”. Journal of Veterinary Internal Medicine, vol. 26, 2012, pp. 1337-1349. cited by applicant
Takeda et al., “Normalization of Left Ventricular Parameters Following Combined Pimobendan and Carvedilol Treatment in a Case of Unclassified Cardiomyopathy with Longstanding Refractory Status”. Internal Medicine, vol. 41, No. 12, Dec. 2002, pp. 1147-1152. cited by applicant
The American Heritage Dictionary, homogeneous, Last Accessed Feb. 10, 2011, 1 page, http://www.xreferplus.com/entry/hmdictenglang/homogeneous. cited by applicant
Thiel et al., “Content uniformity of microdose tablets (dosage 1 μg-10 mg) produced by fluid bed granulation of interactive mixtures”. Journal of Pharmacy and Pharmacology, vol. 38, 1986, pp. 335-343. cited by applicant
Tomanek et al., “Growth of the Coronary Vasculature in Hypertrophy: Mechanisms and Model Dependence”. Cellular and Molecular Biology Research, vol. 40, No. 2, 1994, pp. 129-136. cited by applicant
Trendelenburg, U. “The Action of Histamine and 5-Hydroxytryptamine on Isolated Mammalian Atria”. The Journal of Pharmacology and Experimental Therapeutics, vol. 130, No. 4, Dec. 1960, pp. 450-460. cited by applicant
Van Meel et al., “Pimobendan Increases Survival of Cardiomyopathie Hamsters”. Journal of Cardiovascular Pharmacology, vol. 13, 1989, pp. 508-509. cited by applicant
Vidal et al., “Making sense of antisense”. European Journal of Cancer, vol. 41, 2005, pp. 2812-2818. cited by applicant
Villar et al., “Ibuprofen, Aspirin and Acetaminophen Toxicosis and Treatment in Dogs and Cats”. Veterinary and Human Toxicology, vol. 40, No. 3, Jun. 1998, pp. 156-162. cited by applicant
Wikipedia, the Free Encyclopedia, “Milrinone”. [Accessed at: http://en.wikipedia.org/wiki/Milrinone on Mar. 10, 2014]. cited by applicant
Wikipedia, the Free Encyclopedia, “Pimobendan”. [Accessed at: http://en.wikipedia.org/wiki/Pimobenan on Mar. 10, 2014]. cited by applicant
Woolley et al., “Effects of Treatment Type on Vertebral Heart Size in Dogs With Myxomatous Mitral Valve Disease”. The Journal of Applied Research in Veterinary Medicine, vol. 5, No. 1, 2007, pp. 43-48. cited by applicant
Bourezg et al., “Redispersible lipid nanoparticles of Spironolactone obtained by three drying methods.” Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 413, 2012, pp. 191-199. cited by applicant
El-Badry et al., “Physicochemical Characterization and Dissolution Properties of Meloxicam-Gelucire 50/13 Binary Systems.” Scientia Pharmaceutica, vol. 79, 2011, pp. 375-386. cited by applicant
Fasinu et al., “Diverse approaches for the enhancement of oral drug bioavailability.” Biopharmaceutics & Drug Disposition, vol. 32, 2011, pp. 185-209. cited by applicant
Lindenberg et al., “Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.” European Journal of Pharmaceutics and Biopharmaceutics, vol. 58, 2004, pp. 265-278. cited by applicant
Nainar et al., “Biopharmaceutical Classification System in In-vitro/In-vivo Correlation: Concept and Development Strategies in Drug Delivery.” Tropical Journal of Pharmaceutical Research, vol. 11, No. 2, Apr. 2012, pp. 319-329. cited by applicant
Upadhyay et al., “Formulation of Fast-Release Gastroretentive Solid Dispersion of Glibenclamide with Gelucire 50/13.” Tropical Journal of Pharmaceutical Research, vol. 11, No. 3, Jun. 2012, pp. 361-369. cited by applicant
Vasconcelos et al., “Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs.” Drug Discovery Today, vol. 12, Nos. 23/24, Dec. 2007, pp. 1068-1075. cited by applicant
Ouellet et al., “Effect of Pimobendan on Echocardiographic Values in Dogs with Asymptomatic Mitral Valve Disease.” Journal of Veterinary Internal Medicine, vol. 23, 2009, pp. 258-263. cited by applicant
Kanno et al., “Effects of Pimobendan for Mitral Valve Regurgitation in Dogs.” Journal of Veterinary Medical Science, vol. 69, No. 4, Apr. 2007, pp.373-377. cited by applicant
Atkins et al., “Pharmacologic management of myxomatous mitral valve disease in dogs.” Journal of Veterinary Cardiology, vol. 14, 2012, pp.165-184. cited by applicant
Boswood et al., “Evaluation of pimobendan in dogs with cardiomegaly caused by preclinical mitral valve disease.” The Veterinary Record, vol. 168, No. 8, Feb. 2011, p. 222. cited by applicant
Boswood et al., “Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and cardiomegaly: the EPIC Study—A Randomized Clinical Trial.” Journal of Veterinary Internal Medicine, vol. 30, 2016, pp. 1765-1779. cited by applicant
Beaufrere et al., “Therapeutic Review: Pimobendan.” Journal of Exotic Pet Medicine, vol. 18, No. 4, Oct. 2009, pp. 311-313. cited by applicant
Tissier R; “Increased Mitral Valve Regurgitation and Myocardial Hypertrophy in Two Dogs With Long-Term Pimobendan Therapy”; Cardiovascular Toxicology (2005) 05, 43-51. cited by applicant
Xu Yunsheng, “Pathology and Pathophysiology” pp. 110-113, China Medical Science and Technology Press, Mar. 2015. cited by applicant
Song Wenxuan et al., “Practical Cardiovascular Drug Therapy”, pp. 336-337, People's Medical Publishing House, Aug. 2001. cited by applicant
Smith PJ, French AT, Van Israrl N et al. “Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease”, (2005) 46 J Small Anim Pract 121-130 (SMITH 2005), published no later than Mar. 2005 or, alternatively, Feb. 10, 2006. cited by applicant
Atkins C, Bonagura J, Ettinger S et al. “Guidelines for the Diagnosis and Treatment of Canine Chronic Valvular Heart Disease”, (2009) 23 Journal ofVeterinary Internal Medicine 1142-1150. cited by applicant
Boyle KL and Leech E “A review of the pharmacology and clinical uses of pimobendan”, (2012) 22(4) Journal of Veterinary Emergency and Critical Care 398-408. cited by applicant
Häggström J, Lord PF, Höglund K et al. “Short Term Hemodynamic and Neuroendocrine Effects of Pimobendan and Benazepril in Dogs with Myxomatous Mitral Valve Disease and Congestive Heart Failure” (2013) 27 Journal of Veterinary Internal Medicine 1452-1462. cited by applicant
Boswood, A., et al. “Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with preclinical myxomatous mitral valve disease receiving pimobendan or placebo: the EPIC study.” Journal of veterinary internal medicine 32.1 (2018): 72-85. cited by applicant
Keene BW, Atkins CE, Bonagura JD, et al. “ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs.” J Vet Intern Med. 2019;1-14. https://doi.org/10.1111/jvim.15488. cited by applicant
Wess, G., et al. “European Society of Veterinary Cardiology screening guidelines for dilated cardiomyopathy in Doberman Pinschers.” Journal of Veterinary Cardiology 19.5 (2017): 405-415. cited by applicant
Oftsson et al., “Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization”. Journal of Pharmaceutical Sciences, vol. 85, No. 10, Oct. 1996, pp. 1017-1025. cited by applicant
“Global clinical trial into effects of Pimobendan in dogs with Cardiomegaly (EPIC)”; Royal Veterinary Colleage—London; Mar. 17, 2015. cited by applicant
Boswood, Adrian. “Valvular heart disease in the dog.” Veterinary Focus 18.3 (2008): 25. cited by applicant
Boswood, Adrian. “Current use of pimobendan in canine patients with heart disease.” Veterinary Clinics: Small Animal Practice 40.4 (2010): 571-580. cited by applicant
Boswood 2017, Textbook of Veterinary Internal Medicine, Chapter 247, 8th edition, p. 1163-1176. cited by applicant
Boswood, Adrian. “Improving outcomes of myxomatous mitral valve disease in dogs.” In Practice 40 (2018): 12-15. cited by applicant
Borgarelli, M., et al. “Survival characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration.” Journal of veterinary internal medicine 26.1 (2012): 69-75. cited by applicant
Borgarelli, M., et al. “DELay of Appearance of symptoms of canine degenerative mitral valve disease treated with spironolactone and benazepril: the DELAY study.” Journal of Veterinary Cardiology 27 (2020): 34-53. cited by applicant
“Pimobendan,” BSAVA 2014, Small Animal Formulary 8th ed, p. 319. cited by applicant
Kvart, Clarence, et al. “Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation.” Journal of veterinary internal medicine 16.1 (2002): 80-88. cited by applicant
Lombard, Christophe W., Olaf Jons, and Claudio M. Bussadori. “Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.” Journal of the American Animal Hospital Association 42.4 (2007): 29-39. cited by applicant
Pouchelon, J-L., et al. “Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases.” Journal of veterinary internal medicine 22.4 (2008): 905-914. cited by applicant
Amsallem, Emmanuel, et al. “Phosphodiesterase III inhibitors for heart failure.” Cochrane Database of Systematic Reviews 1 (2005). cited by applicant
Atkins, Clarke E., et al. “Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency.” Journal of the American Veterinary Medical Association 231.7 (2007): 1061-1069. cited by applicant
Keene et al., “Diseases of the Dog and the Cat,” Textbook of Veterinary Internal Medicine, Chapter 237: Guidelines for the Diagnosis and Treatment of Canine Chronic Valvular Heart Disease, p. 1196-1202. cited by applicant
Fuentes et al., “Diseases of the Dog and the Cat,” Textbook of Veterinary Internal Medicine, Seventh Edition, Chapter 238: Inotropes: Inodilators, 1202-1207. cited by applicant
Schneider, P., et al. “Comparative cardiac toxicity of the IV administered benzimidazole pyridazinon derivative Pimobendan and its enantiomers in female Beagle dogs.” Experimental and Toxicologic Pathology 49.3-4 (1997): 217-224. cited by applicant
Wess, Gerhard, et al. “Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.” Journal of Veterinary Internal Medicine 34.6 (2020): 2232-2241. cited by applicant
“Effect of mobendan in dogs with preclinical myxomatous mitral valve disease and ardiomegaly: The EPIC study—A randomized clinical trial,” Boswood 2016, ACVIM meeting. cited by applicant

edspgr.12011441